The historical record shows that the battle to prevent and find cures for infectious disease will lead to a lower incidence of chronic, disabling diseases. At the same time, efforts to find ...
Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...